secwatch.observer — SEC 8-K summary
======================================

Issuer:     Silexion Therapeutics Corp (SLXN)
CIK:        0002022416
Form:       8-K
Filed at:   2025-11-12T23:59:59+00:00
Accession:  0001178913-25-003756
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Silexion Q3 net loss narrows to $3.3M; cash $9.2M; Phase 2/3 trial on track for H1 2026
--------------------------------------------------------------------------------

- Net loss $3.3M ($2.88/share) vs $11.9M ($274.25) a year ago, aided by lower share-based compensation.
- Cash and equivalents $9.2M as of Sep 30, up from $1.2M at Dec 2024, after raising ~$9.5M in Q3.
- R&D spend $2.2M (-31% YoY); G&A $1.1M (-77% YoY); shareholders' equity improved to $7.0M.
- Phase 2/3 trial of SIL204 in KRAS-driven cancers on track for H1 2026; regulatory submissions planned for Q4 2025/Q1 2026.
- New preclinical data shows SIL204 efficacy across five cancer types, including first gastric cancer evidence.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2022416/000117891325003756/0001178913-25-003756-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2022416/000117891325003756/zk2533972.htm
  HTML page:      https://secwatch.observer/filing/0001178913-25-003756

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer